CPT Q2043 – Cellular Immunotherapy for Prostate Cancer
Code Description HCPCS Q2043 Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GMCSF, including leukapheresis and all other preparatory procedures, per infusion (Provenge®) Cellular Immunotherapy for Prostate Cancer Introduction Immunotherapy is a way to fight disease, even cancer, by using a person’s own immune system. Dendritic cells are part of the immune system. ... Read More
